NVAX — Put-Selling Research

by ThetaLoop Research
← Back to search
Last close: 2026-04-02
Novavax, Inc.
Healthcare · $7.7
3.2
/10
Weak
How this score works →
Regime
Bearish
vs SMA200
SMA200 Distance
-4.2%
Below trend
Volatility
Normal
Average premiums
Momentum
Turning
Price direction
About Novavax, Inc.
Novavax is a biotech focused on protein-based COVID and flu vaccines. Highly volatile and speculative, driven by regulatory decisions, partnership news, and revenue uncertainty. No dividend. CSP premiums are rich from sky-high IV, but binary event risk is severe — suitable only for aggressive, event-aware sellers comfortable with large gaps.
Biotechnology
Market Cap
$1.3B
P/E Ratio
3.0
Beta
2.65
52-Week Range Current: $7.7
$5.01 $11.97
Earnings
2026-05-07
32 days away
📊 View Full Research Track Record (All Wins AND Losses)
These free tools show market conditions and individual scores.
Our daily research goes deeper — covering option-specific data points, strike analysis, and risk metrics delivered via Telegram.
EXPLORE OUR RESEARCH — 14 DAYS FREE